FDA Calendar

Upcoming clinical readouts, trial starts, and trial-progress milestones for U.S.-listed biotech, with official source links.

FREE BETA · Guests can view 30 days, including today (through Nov 10, 2026, ET). Sign in for the full calendar.

2 of 1,611 scheduled catalysts · 2 of 429 companies with matching events

Evidence: A regulator/SEC/trial registry · B official company source · Market data is separate context.

Scheduled catalysts

Scroll the table horizontally to view all columns →

Next CatalystCompanyDrugPrice · 30DCurrent stage

ORIC PHARMACEUTICALS, INC.ORIC

Rinzimetostat (ORIC-944)small molecule

Metastatic castration-resistant prostate cancer previously treated with abirateroneHimalayas-1 · mCRPC patients previously treated with abiraterone acetate

EED / PRC2

Clinical dataConference presentationOct 23, 2026global · ESMO Congress 2026

Himalayas-1 · A Global Phase 3 Study in mCRPC Patients Previously Treated With Abiraterone Acetate (Himalayas-1)

BOfficial source

Current stage

PreINDP1P2P3FilingApproved

Price · 30D

$12.25+1.5%

30D · 10/09

Summit Therapeutics Inc.SMMT

ivonescimab (SMT112)bispecific antibody

first-line treatment of patients with advanced biliary tract cancerHARMONi-GI1 · patients with advanced biliary tract cancer

PD-1 / VEGF

Clinical dataPartner-led: Akeso, Inc. · China · Expected Phase 3 dataOct 25, 2026China · ESMO 2026

Study details

HARMONi-GI1 · data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab, will be featured

BOfficial source

All sources (5)

Current stage

PreINDP1P2P3FilingApproved

Price · 30D

$17.35+2.1%

30D · 10/09

Showing 2 of 2 available events